<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: indications</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'indications'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22indications%22&t=%22indications%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 03:31:21 +0100</lastBuildDate>
        <item>
            <title>Want To Milk A Cash Cow? Try Pediatric Exclusivity</title>
            <link>http://www.medworm.com/index.php?rid=4040790&amp;cid=t_224170_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FjM0_AEELoGE%2F</link>
            <description>When drugmakers look to milk their existing cash cows just a little more, what&amp;#8217;s the best strategy? Although pediatric exclusivity can certainly boost cash flow, tinkering with a drug&amp;#8217;s underlying science may actually yield more long-term value, according to a report by Cutting Edge Information, which queried 28 drugmakers as part of its study.
What the industry likes to call life cycle management can be pursued through different means, of course. And this includes pediatric exclusivity, new indications, new formulations, patent retention, next generation versions, authorized generics or a form of strategic pricing. But each approach comes with a price. For instance, four of the strategies require clinical trials.
As the chart indicates, pediatric exclusivity is the most profit...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4040790</comments>
            <pubDate>Thu, 07 Oct 2010 12:26:14 +0100</pubDate>
            <guid isPermaLink="false">4040790</guid>        </item>
        <item>
            <title>Indications for THR</title>
            <link>http://www.medworm.com/index.php?rid=2151155&amp;cid=t_224170_83_f&amp;fid=38205&amp;url=http%3A%2F%2Fandreas.medbrains.net%2F2009%2F02%2F02%2Findications-for-thr%2F</link>
            <description>The benefits of total hip and knee replacement have been recognized for a long time. They cost-effectively relieve pain and functional disability in patients with osteoarthritis.
Because this is one of the most common diseases in the second half of life, large numbers of total hip replacements (THRs) are performed each year (eg, about 200,000 THRs in the United States, 150,000 in Germany and 40,000 in the United Kingdom). However, wide variations in the provision of THR have been reported both within and between countries, with rates varying from 15 to 50 procedures per 10,000 inhabitants aged 50 years and older.
There are many possible reasons for these variations, including differences in disease prevalence or severity, different population demographics, differences in expectations of pa...</description>
            <author>Andreas Richards WeBlog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2151155</comments>
            <pubDate>Mon, 02 Feb 2009 09:12:55 +0100</pubDate>
            <guid isPermaLink="false">2151155</guid>        </item>
        <item>
            <title>Investing In New Indications Or New Compounds</title>
            <link>http://www.medworm.com/index.php?rid=1556511&amp;cid=t_224170_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F323194026%2F</link>
            <description>Take a close look at the many uses for Lilly&amp;#8217;s Cymbalta and you could be excused for thinking the drug is a magic pill - the med is approved for treating depression, anxiety and fibromyalgia. In Europe, Cymbalta is taken for treating stress urinary incontinence. Lilly has asked the FDA to approve Cymbalta for chronic knee and low back pain, and is also testing the pill for combating chronic fatigue.
Cymbalta is an example of how drugmakers are pushing hard to find every possible use for their existing meds, writes The Indianapolis Star, in an effort to shore up revenue at a time when successfully developing and winning approval to sell new meds has become harder. Lilly, in fact, hasn&amp;#8217;t launched a new drug for humans in three years, the paper notes.
Lilly, of course, argues its ...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1556511</comments>
            <pubDate>Mon, 30 Jun 2008 12:03:43 +0100</pubDate>
            <guid isPermaLink="false">1556511</guid>        </item>
        <item>
            <title>MDCT for assessing pancreatico-biliary union</title>
            <link>http://www.medworm.com/index.php?rid=463380&amp;cid=t_224170_115_f&amp;fid=34676&amp;url=http%3A%2F%2Fbhavin.typepad.com%2Fradiology%2F2006%2F09%2Fmdct_for_assess.html</link>
            <description>This article, by Itoh S et al , in the September issue of the AJR, shows how MDCT (using 4-slice) can depict the pancreatico-biliary ductal anatomy exceptionally well. This allows the diagnosis of the abnormal channel, especially in patients with choledochal cysts.

Because of the superior spatial resolution with multi-slice scanners, it is highly likely that the results with MSCT for this particular purpose, will be better than MRCP.



We have had a similar experience on our 64-slice CT. This is a child with a choledochal cyst (Fig. 1), where the abnormal pancreatico-biliary channel is extremely well seen (Figs. 2, 3). (Source: Spot Diagnosis)</description>
            <author>Spot Diagnosis</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=463380</comments>
            <pubDate>Thu, 14 Sep 2006 03:12:00 +0100</pubDate>
            <guid isPermaLink="false">463380</guid>        </item>
        <item>
            <title>High-resolution MRI lymphangiography</title>
            <link>http://www.medworm.com/index.php?rid=463391&amp;cid=t_224170_115_f&amp;fid=34676&amp;url=http%3A%2F%2Fbhavin.typepad.com%2Fradiology%2F2006%2F08%2Fhighresolution_.html</link>
            <description>A new technical innovation from Germany, by Lohrmann C et al, in the August issue of the AJR, shows how we can perform high-resolution MRI lymphangiography using gadodiamide (Omniscan), by injecting it into the web-spaces of the toes and imaging approximately 45-60 minutes later. The lymphatic vessels are very well seen and patients with lymphedema can thus be imaged.

Considering that traditional lymphangiography is so difficult nowadays to perform, especially due to the lack of availability of Lipiodol, this should be an attactive technique to use. (Source: Spot Diagnosis)</description>
            <author>Spot Diagnosis</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=463391</comments>
            <pubDate>Thu, 31 Aug 2006 12:49:00 +0100</pubDate>
            <guid isPermaLink="false">463391</guid>        </item>
    </channel>
</rss>

